Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Prospect Venture Partners Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
5,636,351Website Global Rank
1,670Website Monthly Traffic
Twitter Followers
Description
Prospect Venture Partners is a venture capital firm with over $1B of capital under management. The firm is dedicated to investing in outstanding biopharmaceutical and medical device companies. Prospect targets commercially attractive biomedical enterprises with outstanding entrepreneurial management teams, proprietary products, and innovative technologies with the potential for significant investment returns. The firm invests in companies with a wide variety of development and financing requirements including new company incubations, first and second venture financing rounds, and later stage private and public companies with proven business models requiring expansion capital.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 8/2009 | Gloucester Pharmaceuticals | Series D | 29M |
| 3/2008 | SurgRx | Series G | 19.8M |
| 7/2004 | Trubion Pharmaceuticals | Series B | 32M |
| 11/2005 | Nanosys | Series C | 0 |
| 7/2010 | DFine | Venture Round | 36.2M |
| 4/2007 | Aspen MedTech | Venture Round | 1M |
| 6/2004 | Rejuvenon | Series B | 37M |
| 6/2012 | SentreHEART | Series C | 26M |
| 9/2004 | SurgRx | Series D | 11.9M |
| 8/2010 | Complete Genomics | Series E | 39M |
| 4/2007 | SurgRx | Series F | 20M |
| 7/2007 | Neomend | Series C | 6M |
| 11/2011 | NGM Biopharmaceuticals | Series B | 55.4M |
| 9/2008 | Baxano | Series B | 20M |
| 10/2010 | NinePoint Medical | Series A | 33M |
| 4/2014 | Nora Therapeutics | Series B | 18M |
| 1/2009 | Satori Pharmaceuticals | Series A | 22M |
| 3/2004 | Phylogix Inc. | Series B | 12M |
| 4/2004 | Archemix | Series B | 50M |
| 1/2010 | Neomend | Series D | 30M |
| 7/2006 | Kythera Biopharmaceuticals | Series B | 30M |
| 5/2008 | Kythera Biopharmaceuticals | Series C | 0 |
| 10/2010 | Pathwork Diagnostics | Series C | 30M |
| 2/2002 | Nanosys | Series A | 15M |
| 6/2010 | Baxano | Series C | 30M |
| 9/2005 | Amicus Therapeutics | Series C | 55M |
| 10/2009 | Lux Biosciences | Series B | 50M |
| 8/2009 | Complete Genomics | Series D | 45M |
| 7/2009 | Somaxon Pharmaceuticals | Post-IPO Equity | 6M |
| 6/2002 | Infinity Pharmaceuticals | Series B | 0 |
| 8/2003 | Rinat Neuroscience | Series B | 40M |
| 12/2003 | Portola Pharmaceuticals | Series A | 21M |
| 11/2005 | Portola Pharmaceuticals | Series B | 46M |
| 7/2008 | Portola Pharmaceuticals | Series C | 60.1M |
| 9/2006 | Alvine Pharmaceuticals | Series A | 21.5M |
| 7/2003 | Tercica | Series B | 44M |
| 6/2004 | Idun Pharmaceuticals | Venture Round | 0 |
| 4/2003 | Nanosys | Series B | 0 |
| 5/2002 | AVEO Oncology | Series A | 15M |
| 5/2004 | Amicus Therapeutics | Series B | 31M |
| 9/2006 | Amicus Therapeutics | Series D | 60M |
| 8/2005 | Amira Pharmaceuticals | Series A | 3M |
| 4/2008 | Transave | Series D | 35M |
| 10/2003 | AVEO Oncology | Series B | 42.7M |
| 1/2011 | Satori Pharmaceuticals | Series B | 7M |
| 3/2015 | NGM Biopharmaceuticals | Series D | 57.5M |
| 9/2006 | Alvine Pharmaceuticals | Series A | 8M |
| 7/2013 | NGM Biopharmaceuticals | Series C | 50M |
| 9/2016 | SentreHEART | Series D | 35M |
| 5/2006 | Cogentus Pharmaceuticals | Series A | - |
| 10/2004 | Vanda Pharmaceuticals | Series B | 18.5M |
| 12/2007 | Cogentus Pharmaceuticals | Series C | 62.5M |
| 3/2007 | Amira Pharmaceuticals | Series B | 25M |
| 4/2005 | Allux Medical | Series B | 5M |
| 2/2002 | Metreo | Series C | 15M |
| 4/2008 | DFine | Series D | 20M |
| 12/2005 | DFine | Series B | 6.5M |
| 7/2006 | Pathwork Diagnostics | Venture Round | 11M |
| 5/2009 | Visiogen | Series D | 40M |
| 11/2005 | Hansen Medical | Venture Round | - |
| 12/2009 | NGM Biopharmaceuticals | Series A | 26.6M |
| 4/2007 | Cogentus Pharmaceuticals | Series B | 15M |
| 7/2005 | Vitae Pharmaceuticals | Series C | 15M |
| 10/2004 | Gloucester Pharmaceuticals | Series B | 29M |
| 11/2007 | Vitae Pharmaceuticals | Series D | 15M |
| 2/2012 | Satori Pharmaceuticals | Venture Round | 15M |
| 3/2014 | Element Science | Series A | 12.5M |
| 3/2004 | Jazz Pharmaceuticals | Series B | 0 |
| 10/2011 | Azelon Pharmaceuticals | Series A | 4.5M |
| 6/2005 | Verus Pharmaceuticals | Series A | 0 |
| 6/2005 | Somaxon Pharmaceuticals | Series C | 0 |
| 11/2006 | Amira Pharmaceuticals | Series A | 4M |
| 9/2011 | Kythera Biopharmaceuticals | Series D | 0 |
| 1/2004 | Vitae Pharmaceuticals | Series B | 15M |
| 9/2004 | Allux Medical | Series A | 800k |
| 5/2005 | AVEO Oncology | Series C | 5M |
| 2/2007 | Visiogen | Venture Round | 24M |
| 3/2014 | NinePoint Medical | Series B | 34M |
| 10/2011 | Topica Pharmaceuticals | Series B | 27M |
| 1/2010 | DFine | Venture Round | 0 |
| 8/2002 | Biospect | Series A | 4M |
| 11/2011 | DFine | Venture Round | 25M |
| 1/2009 | DFine | Venture Round | 0 |
| 10/2005 | Roxro Pharma | Series B | 21.6M |
| 3/2002 | Signature BioScience | Series E | 0 |
| 6/2003 | Opus Medical | Series C | 13.6M |
| 6/2007 | Roxro Pharma | Series B | 42.7M |
| 8/2002 | Archemix | Series A | 51.8M |
| 1/2011 | SurePoint Medical | Venture Round | - |
| 9/2016 | SentreHEART | Series D | 0 |
| 3/2015 | NGM Biopharmaceuticals | Series D | 0 |
| 4/2014 | Nora Therapeutics | Series B | 0 |
| 3/2014 | Element Science | Series A | 0 |
| 3/2014 | NinePoint Medical | Series B | 0 |
| 7/2013 | NGM Biopharmaceuticals | Series C | 0 |
| 6/2012 | SentreHEART | Series C | 0 |
| 2/2012 | Satori Pharmaceuticals | Venture Round | 0 |
| 11/2011 | DFine | Venture Round | 0 |
| 11/2011 | NGM Biopharmaceuticals | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
